AstraZeneca reports Q1 net loss of Rs 12 cr, total income at Rs 396 cr

Q: How long will it take to read this news story?

The story "AstraZeneca reports Q1 net loss of Rs 12 cr, total income at Rs 396 cr" has 214 words across 7 sentences, which will take approximately 1 - 2 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "AstraZeneca reports Q1 net loss of Rs 12 cr, total income at Rs 396 cr" was covered 11 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 345 news stories per day. It's most recent story was published 4 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #21985889</li><li>URL: https://beamstart.com/news/astrazeneca-reports-q1-net-loss-17231270909002</li></ul>

Business Standard Logo Business Standard 11h ago

AstraZeneca reports Q1 net loss of Rs 12 cr, total income at Rs 396 cr - Business Standard

Quick Summary:

"We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programmes focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers and non-government organisations," AstraZeneca India Country President and Managing Director Sanjeev Panchal said.

AstraZeneca Pharma India on Thursday said its net loss stood at Rs 12 crore for the first quarter ended June 30, 2024.

Total income stood at Rs 396 crore for the June quarter against Rs 303 crore in the year-ago period, AstraZeneca Pharma India said in a regulatory filing.